Heron Therapeutics Inc vs T1 Energy Inc. Common Stock — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $74.18M), while T1 Energy Inc. Common Stock trades at $2.74 (market cap $946.42M). The key difference: T1 Energy Inc. Common Stock is far larger — about 12.8× Heron Therapeutics Inc's market cap, and T1 Energy Inc. Common Stock is more actively traded (12,898,774 versus 1,857,401). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 36 Days and T1 Energy Inc. Common Stock for 0 Days on average.
| HRTX | TE | |
|---|---|---|
Market Cap | $74.18M | $946.42M |
Volume | 1,857,401 | 12,898,774 |
Sector | Health | Industrials |
52-Week High | $1.49 | $12.04 |
52-Week Low | $0.27 | $2.72 |
Typical Hold Time | 36 Days | 0 Days |
Enterprise Value | $180.92M | $1.72B |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3906, down 6.02% today, with a bullish technical signal from moving averages and oscillators. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates. Despite a high gross margin of 70.07%, it posted a net loss of -$20.20 million in 2025. Analyst consensus is strongly positive with 17 buy ratings. Recent news highlights earnings results and competitive comparisons.
The outlook remains speculative given persistent losses and negative ROE, but strong analyst support and improving cash flow trends offer potential upside. Key risks include profitability challenges and revenue volatility. Investors should weigh the bullish sentiment against fundamental weaknesses.
T1 Energy (TE) trades at $3.16, down 1.56% today, reflecting ongoing investor caution despite a mixed earnings history. The company shows significant revenue growth from $755M in 2025 to $997M in 2026 but remains deeply unprofitable with a -38.49% net margin. Recent news highlights strategic moves toward vertical integration in solar manufacturing and energy storage, including the G2_Austin facility development and new supply agreements, which are central to its growth narrative.
The investment case hinges on execution of vertical integration and policy tailwinds, offering substantial upside to the $8 consensus target, but high execution risk, persistent losses, and regulatory scrutiny present clear dangers. Analyst sentiment is mixed with a Moderate Buy rating, yet the stock's viability depends heavily on future profitability improvements from 2027 onward.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →T1 Energy Inc. manufactures photovoltaic solar modules and cells in US, operating a solar manufacturing facility in Texas acquired from Trina Solar. The company was formerly known as FREYR Battery before rebranding as T1 Energy in 2025 and changing its NYSE ticker from FREY to TE.
Read more on TE →